QOL Medical to purchase Evoke Pharma for $11.00 per share in cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy ?
Acquisition Details: QOL Medical will acquire Evoke Pharma for $11.00 per share in cash, a deal unanimously approved by both companies' Boards of Directors, expected to close by the end of 2025.
Strategic Value: The acquisition highlights the strategic importance of Evoke's product, GIMOTI, the first FDA-approved nasal spray for treating diabetic gastroparesis in adults.
Tender Offer Conditions: QOL Medical will initiate a tender offer for all outstanding shares of Evoke, contingent on the tender of a majority of shares and other customary closing conditions.
Financing and Timeline: The transaction will be financed with cash on hand and is anticipated to close in the fourth quarter of 2025, without any financing condition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
